Abstract
Background: Asthma epidemics associated with thunderstorms have had catastrophic effects on individuals and emergency services. Seasonal allergic rhinitis (SAR) is present in the vast majority of people who develop thunderstorm asthma (TA), but there is little evidence regarding risk factors for TA among the SAR population. Objective: We sought to identify risk factors for a history of TA and hospital presentation in a cohort of individuals with SAR. Methods: This multicenter study recruited adults from Melbourne, Australia, with a past diagnosis of TA and/or self-reported SAR. Clinical information, spirometry results, white blood cell count, ryegrass pollen–specific (RGP-sp) IgE concentration, and fractional exhaled nitric oxide were measured to identify risk factors for a history of TA in individuals with SAR. Results: From a total of 228 individuals with SAR, 35% (80 of 228) reported SAR only (the I-SAR group), 37% (84 of 228) reported TA symptoms but had not attended hospital for treatment (the O-TA group), and 28% (64 of 228) had presented to the hospital for TA (the H-TA group). All patients in the H-TA group reported a previous asthma diagnosis. Logistic regression analysis of factors associated with O-TA and H-TA indicated that lower FEV1 value and an Asthma Control Questionnaire score higher than 1.5 were associated with H-TA. Higher blood RGP-sp IgE concentration, eosinophil counts, and fractional exhaled nitric oxide level were significantly associated with both O-TA and H-TA. Receiver operating curve analysis showed an RGP-sp IgE concentration higher than 10.1 kU/L and a prebronchodilator FEV1 value of 90% or lower to be biomarkers of increased H-TA risk. Conclusion: Clinical tests can identify risk of a history of TA in individuals with SAR and thereby inform patient-specific treatment recommendations.
Original language | English |
---|---|
Pages (from-to) | 1607-1616 |
Number of pages | 10 |
Journal | The Journal of Allergy and Clinical Immunology |
Volume | 149 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2022 |
Keywords
- ACQ
- Asthma
- epidemic
- ryegrass pollen
- seasonal allergic rhinitis
- specific IgE
- spirometry
- thunderstorm
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Journal of Allergy and Clinical Immunology, Vol. 149, No. 5, 05.2022, p. 1607-1616.
Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Thunderstorm asthma in seasonal allergic rhinitis
T2 - The TAISAR study
AU - Douglass, Jo A.
AU - Lodge, Caroline
AU - Chan, Samantha
AU - Doherty, Alice
AU - Tan, Ju Ann
AU - Jin, Celina
AU - Stewart, Alastair
AU - Southcott, Anne M.
AU - Gillman, Andrew
AU - Lee, Joy
AU - Csutoros, Danny
AU - Hannan, Liam
AU - Ruane, Laurence
AU - Barnes, Sara
AU - Irving, Lou
AU - Harun, Nur Shirin
AU - Lachapelle, Phillipe
AU - Spriggs, Kymble
AU - Sutherland, Michael
AU - See, Katharine
AU - McDonald, Christine F.
AU - Conron, Matthew
AU - Radhakrishna, Naghmeh
AU - Worsnop, Christopher
AU - Johnston, Fay H.
AU - Davies, Janet M.
AU - Bryant, Vanessa
AU - Iles, Linda
AU - Ranson, David
AU - Spanos, Paresa
AU - Vicendese, Don
AU - Lowe, Adrian
AU - Newbigin, Edward J.
AU - Bardin, Philip
AU - Dharmage, Shyamali
N1 - Funding Information: Disclosure of potential conflict of interest: J. A. Douglass reports receiving honoraria for educational presentations from AstraZeneca, GSK, Novartis, Alphapharm, Shire, and CSL; serving on advisory boards for Sanofi-Aventis, Novartis, GSK, AstraZeneca, Shire, Immunosis and CSL; and performing contracted or investigator-initiated research on behalf of GSK, Novartis, Immunosis, AstraZeneca, Sanofi-Aventis, Grifols, CSL, BioCryst, and Equilium; in addition, she has a personal superannuation shareholding in CSL. S. Chan reports grants from Medical Research Future Fund during the conduct of the study, as well as grants, personal fees, and nonfinancial support from CSL and nonfinancial support from Sanofi outside the submitted work. J. M. Davies reports grants from the National Health and Medical Research Council (Australia), the Australian Research Council, the Emergency Medicine Foundation, the Victorian Government Department of Health and Human Services, the Australian Bureau of Meteorology, and the National Foundation of Medical Research Innovation outside the submitted work; in addition, with the institute QUT, she has patent US PTO 14/311944 issued, patent PCT/AU2014/000630/WO2014_201499 pending, patent PCT/AU2015/050348 pending, and patent AU2008/316301 issued; she led the NHMRC AusPollen Partnership Project (GNT 1116107) with matching cash and in kind cosponsorship from the Australasian Society for Clinical Immunology and Allergy, Asthma Australia, the Bureau of Meteorology, Commonwealth Scientific and Industrial Research Organisation, Stallergenes Australia, and the Federal Office of Meteorology and Climatology MeteoSwiss, Switzerland; and she was the investigator of a National Foundation for Medical Research Innovation grant with cosponsorship from Abionic Switzerland; J. Lee reports fees for providing unrelated independent medical advice for GlaxoSmithKline and speaker fees for medical education purposes from Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca outside the submitted work. C. Worsnop reports speakers and personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Mundipharma, Sequirus, Mylan, Alfred Lung Health Promotion Unit, HealthEd, and Amaco outside the submitted work. C. F. McDonald reports speakers fees from AstraZeneca and Menari (directed to her institution) outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: We thank the following individuals and organizations for their contributions to the study: Susanne Schulz, Cara Brookes, Geri Shandler, Fiona Sultana, Maria Bisignano, Trudi Harris, Narelle Tunstall, Xin Li, Shenna Langenbach, Qianyu Chen, Jo McKenzie, Natalie Deeble, Sandra Cork, Lauren Tampaline, Nicholas Romeo, Lisa Furhmeister, Sue Brenton, Sarah Matthews, Tamara Matthews, Valerie Yee, Sue Casanelia, Chris Lucani, Angela Watt, Angela Magira, Asthma Australia, National Asthma Council, and the volunteers. Supported by a grant from the Medical Research Future Fund's Rapid Applied Research Translation program in conjunction with the Melbourne Academic Centre for Health (GO162-MACH). The study funder had no role in the study design; collection, analysis, and interpretation of data; writing of the report; and decision to submit for publication. All authors had full access to all data in the study and accept responsibility for submission of the final draft. Disclosure of potential conflict of interest: J. A. Douglass reports receiving honoraria for educational presentations from AstraZeneca, GSK, Novartis, Alphapharm, Shire, and CSL; serving on advisory boards for Sanofi-Aventis, Novartis, GSK, AstraZeneca, Shire, Immunosis and CSL; and performing contracted or investigator-initiated research on behalf of GSK, Novartis, Immunosis, AstraZeneca, Sanofi-Aventis, Grifols, CSL, BioCryst, and Equilium; in addition, she has a personal superannuation shareholding in CSL. S. Chan reports grants from Medical Research Future Fund during the conduct of the study, as well as grants, personal fees, and nonfinancial support from CSL and nonfinancial support from Sanofi outside the submitted work. J. M. Davies reports grants from the National Health and Medical Research Council (Australia), the Australian Research Council, the Emergency Medicine Foundation, the Victorian Government Department of Health and Human Services, the Australian Bureau of Meteorology, and the National Foundation of Medical Research Innovation outside the submitted work; in addition, with the institute QUT, she has patent US PTO 14/311944 issued, patent PCT/AU2014/000630/WO2014_201499 pending, patent PCT/AU2015/050348 pending, and patent AU2008/316301 issued; she led the NHMRC AusPollen Partnership Project (GNT 1116107) with matching cash and in kind cosponsorship from the Australasian Society for Clinical Immunology and Allergy, Asthma Australia, the Bureau of Meteorology, Commonwealth Scientific and Industrial Research Organisation, Stallergenes Australia, and the Federal Office of Meteorology and Climatology MeteoSwiss, Switzerland; and she was the investigator of a National Foundation for Medical Research Innovation grant with cosponsorship from Abionic Switzerland; J. Lee reports fees for providing unrelated independent medical advice for GlaxoSmithKline and speaker fees for medical education purposes from Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca outside the submitted work. C. Worsnop reports speakers and personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Mundipharma, Sequirus, Mylan, Alfred Lung Health Promotion Unit, HealthEd, and Amaco outside the submitted work. C. F. McDonald reports speakers fees from AstraZeneca and Menari (directed to her institution) outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Supported by a grant from the Medical Research Future Fund’s Rapid Applied Research Translation program in conjunction with the Melbourne Academic Centre for Health (GO162-MACH). The study funder had no role in the study design; collection, analysis, and interpretation of data; writing of the report; and decision to submit for publication. All authors had full access to all data in the study and accept responsibility for submission of the final draft. Publisher Copyright: © 2021
PY - 2022/5
Y1 - 2022/5
N2 - Background: Asthma epidemics associated with thunderstorms have had catastrophic effects on individuals and emergency services. Seasonal allergic rhinitis (SAR) is present in the vast majority of people who develop thunderstorm asthma (TA), but there is little evidence regarding risk factors for TA among the SAR population. Objective: We sought to identify risk factors for a history of TA and hospital presentation in a cohort of individuals with SAR. Methods: This multicenter study recruited adults from Melbourne, Australia, with a past diagnosis of TA and/or self-reported SAR. Clinical information, spirometry results, white blood cell count, ryegrass pollen–specific (RGP-sp) IgE concentration, and fractional exhaled nitric oxide were measured to identify risk factors for a history of TA in individuals with SAR. Results: From a total of 228 individuals with SAR, 35% (80 of 228) reported SAR only (the I-SAR group), 37% (84 of 228) reported TA symptoms but had not attended hospital for treatment (the O-TA group), and 28% (64 of 228) had presented to the hospital for TA (the H-TA group). All patients in the H-TA group reported a previous asthma diagnosis. Logistic regression analysis of factors associated with O-TA and H-TA indicated that lower FEV1 value and an Asthma Control Questionnaire score higher than 1.5 were associated with H-TA. Higher blood RGP-sp IgE concentration, eosinophil counts, and fractional exhaled nitric oxide level were significantly associated with both O-TA and H-TA. Receiver operating curve analysis showed an RGP-sp IgE concentration higher than 10.1 kU/L and a prebronchodilator FEV1 value of 90% or lower to be biomarkers of increased H-TA risk. Conclusion: Clinical tests can identify risk of a history of TA in individuals with SAR and thereby inform patient-specific treatment recommendations.
AB - Background: Asthma epidemics associated with thunderstorms have had catastrophic effects on individuals and emergency services. Seasonal allergic rhinitis (SAR) is present in the vast majority of people who develop thunderstorm asthma (TA), but there is little evidence regarding risk factors for TA among the SAR population. Objective: We sought to identify risk factors for a history of TA and hospital presentation in a cohort of individuals with SAR. Methods: This multicenter study recruited adults from Melbourne, Australia, with a past diagnosis of TA and/or self-reported SAR. Clinical information, spirometry results, white blood cell count, ryegrass pollen–specific (RGP-sp) IgE concentration, and fractional exhaled nitric oxide were measured to identify risk factors for a history of TA in individuals with SAR. Results: From a total of 228 individuals with SAR, 35% (80 of 228) reported SAR only (the I-SAR group), 37% (84 of 228) reported TA symptoms but had not attended hospital for treatment (the O-TA group), and 28% (64 of 228) had presented to the hospital for TA (the H-TA group). All patients in the H-TA group reported a previous asthma diagnosis. Logistic regression analysis of factors associated with O-TA and H-TA indicated that lower FEV1 value and an Asthma Control Questionnaire score higher than 1.5 were associated with H-TA. Higher blood RGP-sp IgE concentration, eosinophil counts, and fractional exhaled nitric oxide level were significantly associated with both O-TA and H-TA. Receiver operating curve analysis showed an RGP-sp IgE concentration higher than 10.1 kU/L and a prebronchodilator FEV1 value of 90% or lower to be biomarkers of increased H-TA risk. Conclusion: Clinical tests can identify risk of a history of TA in individuals with SAR and thereby inform patient-specific treatment recommendations.
KW - ACQ
KW - Asthma
KW - epidemic
KW - ryegrass pollen
KW - seasonal allergic rhinitis
KW - specific IgE
KW - spirometry
KW - thunderstorm
UR - http://www.scopus.com/inward/record.url?scp=85120501475&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2021.10.028
DO - 10.1016/j.jaci.2021.10.028
M3 - Article
AN - SCOPUS:85120501475
SN - 0091-6749
VL - 149
SP - 1607
EP - 1616
JO - The Journal of Allergy and Clinical Immunology
JF - The Journal of Allergy and Clinical Immunology
IS - 5
ER -